Patent intelligence · US
US 9913841
6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
Patent details — US 9913841
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 13, 2018
- Expiration
- Mar 8, 2038
- Applicant
- Sulfateq B.V.
- Claims
- 8
- CPC classes
- A61K, A61K31/353, A61K31/355, A61K31/4025
Quick answer
US 9913841 (6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases) is held by Sulfateq B.V.. Status: granted. Granted Mar 13, 2018. Expires Mar 8, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sulfateq B.V.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/353, A61K31/355, A61K31/4025, A61K31/453, A61K31/496
More from Sulfateq B.V.
Related pharmaceutical patents in our USPTO index.
-
US 12419870
Compositions and methods for immune cell modulation in adoptive immunotherapies
granted -
US 12410403
Methods and compositions for inducing hematopoietic cell differentiation
granted -
US 12398373
Enhanced immune effector cells and use thereof
granted -
US 12385012
Methods and compositions for inducing hematopoietic cell differentiation
granted -
US 12281329
Compositions and methods for immune cell modulation in adoptive immunotherapies
granted -
US 12275955
Combining iPSC derived effector cell types for immunotherapy use
granted -
US 12264322
Minimal volume reprogramming of mononuclear cells
granted -
US 12247226
Cellular reprogramming using temporal and transient plasmid vector expression system
granted
Frequently asked questions
What is US patent 9913841?
US 9913841 (6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases) is held by Sulfateq B.V.. Status: granted. Granted Mar 13, 2018. Expires Mar 8, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9913841?
Sulfateq B.V. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.
When does US 9913841 expire?
Our index shows an expiration date of Mar 8, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.